Thus, GGAP2 is the most commonly mutated oncogene in human prostate cancer to date but the mutations are heterogeneous rather than clonal, implying marked clonal heterogeneity in clinically localized human prostate cancers. The gene discussed is AGAP2; the disease is prostate carcinoma.